

Keystone Symposia: HIV Vaccines (Joint with "Viral Immunity")

part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

March 21–26, 2010 • Fairmont Banff Springs • Banff, Alberta • Canada

Scientific Organizers: Wayne C. Koff, Lynn Morris and Marcus Altfeld

PROGRAM FACULTY & TALKS

Marcus Altfeld*, Massachusetts General Hospital, USA
Natural Killer Cell Function in HIV Infection

Dennis R. Burton^o, The Scripps Research Institute, USA
HIV Env and Approaches to Neutralizing Abs

Shane Crotty^o, La Jolla Institute for Allergy and Immunology, USA
Lessons from the Smallpox Vaccine

Mariapia A. Degli-Esposti, LEI, University of Western Australia, Australia
NK/DC Crosstalk and Regulation of Adaptive Immunity

Peter C. Doherty^o, University of Melbourne, Australia
Anti-Viral Immunity: Lessons from Influenza Virus

Ian H. Frazer^o, University of Queensland, Australia
Lessons from Human Papillomavirus Vaccine

Nathalie Garcon, GlaxoSmithKline, Belgium
Adjuvants to Potentiate Vaccines

Ronald N. Germain^o, NIAID, National Institutes of Health, USA
Intravital Imaging of Adaptive Immune Effector Activity

Ashley T. Haase^o, University of Minnesota, USA
In Vivo Imaging of the Anti-HIV Response

Kim J. Hasenkrug^o, NIAID, National Institutes of Health, USA
Adaptive Immunity to Retroviruses

Barton F. Haynes, Duke University Medical Center, USA
B-Cell Immune Responses to Acute HIV Infection

Heather D. Hickman^o, NIAID, National Institutes of Health, USA
Intravital Imaging of the Host Response to Virus

Eric Hunter, Emory University, USA
Recently Transmitted HIV and the Early Neutralizing Antibody Response

R. Paul Johnson, Harvard Medical School, USA
Lessons from Live Attenuated SIV

Wayne C. Koff^o, International AIDS Vaccine Initiative, USA
Future Directions in AIDS Vaccine Development

Bette T. Korber, Los Alamos National Laboratory, USA
HIV Antigen Designs to Address HIV Variability

Richard A. Koup, National Institutes of Health, USA
Adaptive Immunity to HIV

Peter D. Kwong, Vaccine Research Center, National Institutes of Health, USA
HIV Env Structure

M. Juliana McElrath^o, Fred Hutchinson Cancer Research Center, USA
Lessons from the STEP Trial and the Current Clinical Pipeline

Andrew J. McMichael*, John Radcliffe Hospital, UK
Lessons from Acute HIV Infection

Lynn Morris*, National Institute for Communicable Diseases, South Africa
How Does Neutralization Breadth Develop in HIV Infection?

Louis J. Picker*, Oregon Health & Science University, USA
Cytomegalovirus Vectors

Bali Pulendran^o, Emory University, USA
Lessons from Yellow Fever Vaccine

Quentin J. Sattentau, Sir William Dunn School of Pathology, UK
Inducing Mucosal HIV-1 Antibodies in an Anti-Inflammatory Environment

Barbara L. Shacklett, University of California, Davis, USA
Mucosal Immune Responses to HIV Infection

Guido Silvestri, University of Pennsylvania School of Medicine, USA
Nonpathogenic Natural SIV Infection

Bruce D. Walker^o, Massachusetts General Hospital, USA
Durable Control of HIV Infection: Implications for Vaccine Design

David I. Watkins^o, University of Wisconsin-Madison, USA
Approaches to Overcome CTL Escape

Jonathan W. Yewdell^o, National Institutes of Health, USA
Antigenic Drift in the Influenza HA

*Keynote speaker. *Session chair. ^oJoint speaker.

Program subject to change. Current as of October 20, 2009.



Recent clinical trials, and in particular the STEP trial of Merck's adenovirus AIDS vaccine candidate, have produced results disappointing to the AIDS vaccine field generally, and have given rise to the sobering realization that the majority of vaccine candidates currently under development are unlikely to provide a truly effective AIDS vaccine. Hence, there is now a broad consensus that the field needs to return to some fundamentals of immunology and address how the human (and simian) immune system interacts with HIV and what will be required in an effective immune response against HIV to ward off establishment of infection. To stimulate new insights and approaches regarding these longstanding problems, we are offering a novel conference format to facilitate a wider cross-fertilization of ideas among the wider vaccine research community by means of new joint symposia on HIV Vaccines and Viral Immunity, instead of the traditional pairing of the HIV Pathogenesis and HIV Vaccines meetings. These new concurrent symposia will allow AIDS vaccine researchers to interact with viral immunologists. The meeting should foster innovative ideas and new collaborations between immunology and vaccinology, as it pertains to other viral diseases.

PROGRAM PLENARY SESSIONS & WORKSHOPS:

- Adaptive Immunity/T- and B-Cell Responses
- Workshop 1: Advances in Vaccine Development: Clinical Trials
- Control of HIV Infection
- Neutralizing Antibody
- Workshop 2: Novel Vector and Adjuvant Development
- Innate Immunity
- Vaccines: Immunologic Mechanisms of Action (Joint)
- Workshop 3: Late-Breaker Session
- Imaging of the Antiviral Immune Response (Joint)
- Novel Vaccine Approaches
- Antigenic Variation (Joint)

DEADLINES:

Abstract & Scholarship: November 19, 2009

Late-Breaking Abstract: December 23, 2009

Early Registration: January 21, 2010

www.keystonesymposia.org/10X5

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

PO Box 1630 • Silverthorne, CO 80498 • USA
www.keystonesymposia.org • 1-800-253-0685 • 1-970-262-1230